Zacks.com on MSN3d
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...
PharmExec3d
Phase II Trial Shows Combination of Rybrevant Plus Lazcluze Significantly Reduces Moderate-to-Severe Skin, Nail Reactions in EGFR-Mutated NSCLC
Results from the COCOON study showed that Rybrevant plus Lacluze reduced grade 2 or higher dermatologic events by 50% ...
CURE2d
COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...
Fierce Pharma7d
J&J combo signals new era in EGFR lung cancer with survival win against AstraZeneca's Tagrisso
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
J&J says Rybrevant/Lazcluze outperforms osimertinib OS in Phase 3 study
Johnson & Johnson announced results for the “gold standard endpoint in cancer treatment” of overall survival from the Phase 3 ...
CURE2d
First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
BioSpace7d
J&J’s Lung Cancer Combo Bests AstraZeneca’s Tagrisso, Reducing Risk of Death 25%
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
pharmaphorum7d
J&J throws the gauntlet down to AZ with new survival data
Johnson & Johnson has been saying for some time that it thinks its combination of Rybrevant and Lazcluze is the best option ...